IPT001 / HERVolution Therapeutics - LARVOL DELTA

Targeting the dark genome in solid tumors with IPT001: a virus-like particle (VLP)-based immunotherapy against HERV-K with checkpoint blockade synergy (SITC 2025) - "The observed tumor regression and synergy with PD-1 blockade in preclinical models position HERV-K as a compelling cancer antigen with strong clinical translation potential. Future clinical studies are warranted to validate the efficacy of IPT001 as a monotherapy and in combination with standard-of-care treatments, including immune checkpoint inhibitors.Abstract 646 Figure 1Request permissions"

Checkpoint block • Checkpoint inhibition • IO biomarker • Colorectal Cancer • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CD4 • CD8

Dark Genome Biotech HERVolution Therapeutics Announces $11.7M Series A to Advance Treatments for Cancer & Diseases of Aging (PRNewswire) - "HERVolution Therapeutics ApS ('HERVolution'), a dark genome-focused biotechnology company developing immunotherapies to address aging-related diseases, today announced a $11.7 million Series A financing to advance its lead assets toward clinical evaluation. Proceeds will support key activities, including further validating and demonstrating the value of its human endogenous retroviruses (HERV)-targeting approach, cGMP manufacturing in collaboration with SII, initiating Phase 1 studies of its lead asset, investigating indication expansion opportunities, and expanding company infrastructure to support clinical trials...IPT-001 is currently in development in collaboration with SII, with plans to enter the clinic in 2025."

Financing • New trial • Oncology

InProTher Announces EUR 6M Seed Financing with the Participation of the European Innovation Council Fund to Develop First-In-Class Cancer Immunotherapy (PRNewswire) - "InProTher...announces that it has raised EUR 6M Seed funding from private investors, with participation from the European Innovation Council (EIC) Fund. The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development....It plans to enter First-In-Human (FIH) trials in 2024."

Financing • New trial • Oncology • Solid Tumor